Skip to main content
. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3

Fig. 3. Median anti-SARS-CoV-2 IgG reactive antibodies titers measured in binding antibody units/mL (BAU/mL) at 3–6 weeks, 3 months, 6 months and 1 year after the 2nd dose according to the development of breakthrough SARS-CoV-2 infection.

Fig. 3

A Patients with breakthrough SARS-CoV-2 infection had a median of 202.57 BAU/mL (range 0–5714) vs those without SARS-CoV-2 infection median 937 BAU/mL (range 0–10400) (p < 0.001). B Q3-med means median interquartil 75%; Med-Q1, median interquartil 25%; m, mean. C Patients with breakthrough SARS-CoV-2 infection had a median of 70.14 BAU/mL (range 0–2126) vs those without SARS-CoV-2 infection median 379 BAU/mL (range 0–4746) (p < 0.001). D Patients with breakthrough SARS-CoV-2 infection had a median of 302 BAU/mL (range 0–5408) vs those with SARS-CoV-2 infection median 907 BAU/mL (range 0–11800) (p < 0.001). E Patients with breakthrough SARS-CoV-2 infection had a median of 1017 BAU/mL (range 0–6423) vs those without SARS-CoV-2 infection median 2080 (range 0–15600) (p < 0.001).